business
Novo Nordisk sues Eli Lilly, alleging the company's GLP-1 ads are 'deliberately false'
Summary by The Nashville Editorial Desk · Based on reporting by Scripps News Group , NewsChannel 5 WTVF (CBS affiliate)
· July 21, 2026
· 1 min read
Novo Nordisk, maker of the popular medications Ozempic and Wegovy, filed a lawsuit Tuesday against the pharmaceutical company Eli Lilly, accusing it of making deceptive advertising claims about its weight-loss drug Zepbound. The company has taken issue with Eli Lilly's ads that claim patients on ...
Story provenance No corrections
Summary created by The Nashville Editorial Desk — automated, rule-governed Original reporting Scripps News Group, NewsChannel 5 WTVF (CBS affiliate) Original story Read at the source Source published Jul 21, 2026 Indexed here Jul 21, 2026 AI assistance Automated summary drawn from the source’s own published text Prepublication human review No — editorial rules, flagged-item review, and published samples
Every story comes with a passport. How we work · Corrections log
Key takeaway RELATED STORY | Medicare will start covering weight-loss drugs on July 1 for the first time The company said the ads also lead consumers to believe Eli Lilly's medication is superior to Novo Nordisk's.
Why this matters in The Nashville
The lawsuit between Novo Nordisk and Eli Lilly has significant implications for Nashville's healthcare community, particularly with Medicare set to start covering weight-loss drugs on July 1. As local patients and healthcare providers consider their options, the accuracy of advertising claims will play a crucial role in informed decision-making. Novo Nordisk's allegations that Eli Lilly's ads are deceptive and based on outdated clinical trials could impact the way pharmaceutical companies market their products in the Nashville area. The fact that Zepbound and Wegovy are GLP-1s with different active ingredients, yet similar effects on the body, adds complexity to the issue. With Nashville's large senior population potentially benefiting from Medicare's expanded coverage, the outcome of this lawsuit will be closely watched by local healthcare stakeholders, who will be eager to see how the dispute is resolved and what it means for access to effective and accurately represented weight-loss treatments.
About this story
Original reporting by NewsChannel 5 WTVF (CBS affiliate) . The Nashville surfaces reporting from trusted publishers and adds local editorial context so readers can quickly understand what a story means for their community. We attribute every source, link to the original report, and follow a documented editorial standards policy. To understand how stories are selected and reviewed, read our about page .
For the complete original report, visit NewsChannel 5 WTVF (CBS affiliate) . Have a tip or correction? Contact our newsroom .
Category: business ·
Published: July 21, 2026 ·
Source: NewsChannel 5 WTVF (CBS affiliate) ·
Reading time: 1 min
Frequently asked about this story
What is this story about? Novo Nordisk, maker of the popular medications Ozempic and Wegovy, filed a lawsuit Tuesday against the pharmaceutical company Eli Lilly, accusing it of making deceptive advertising claims about its weight-loss drug Zepbound. The company has taken issue with Eli Lilly's ads that claim patients on ...
When was this published? This article was first published on July 21, 2026 by NewsChannel 5 WTVF (CBS affiliate) and curated for The Nashville readers.
Who reported this story? This story was reported by Scripps News Group at NewsChannel 5 WTVF (CBS affiliate). To learn more about how The Nashville selects and reviews stories, see our editorial standards .
Where can I find related coverage? See more business coverage from The Nashville, or browse our daily briefing and topic hubs .
← Back to all news
More business →
Today’s briefing
Subscribe to newsletter